Bepirovirsen Reduces Levels of Hepatitis B Surface Antigen, Hepatitis B Virus DNA - Pharmacy Times
8/8/2022 12:00:00 AM2 years 8 months ago
by Ashley Gallagher, Assistant Editor
by Ashley Gallagher, Assistant Editor
The B-Clear study investigated the efficacy and safety of 12- or 24-weeks treatment with bepirovirsen in individuals with chronic hepatitis B.
GSK announced interim results from the B-Clear phase 2b trial, showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B virus(HBV), reduced the levels of hepa… [+3488 chars]
full article...